Celon Pharma S.A. Logo

Celon Pharma S.A.

Researches, develops, and markets innovative drugs for oncology and neurology.

CLN | WAR

Overview

Corporate Details

ISIN(s):
PLCLNPH00015 (+3 more)
LEI:
259400Q0ERJT0NC5DT24
Country:
Poland
Address:
KAZUŃ NOWY MARYMONCKA 15, 05-152 KAZUŃ NOWY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celon Pharma S.A. is an integrated biopharmaceutical company engaged in the research, development, manufacturing, and marketing of modern drugs. Established in 2002, the company focuses on creating innovative therapeutic solutions. Its research and development pipeline concentrates on treatments for neurological diseases, such as Parkinson's disease, and oncology. As a marketing authorization holder, Celon Pharma manages the entire product lifecycle, from advanced scientific discovery and clinical trials to full-scale production and commercialization. The company aims to provide therapies that improve the quality and length of patients' lives.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-10 15:36
Registration Form
Statut - tekst jednolity
Polish 405.4 KB
2025-10-10 15:36
Registration Form
Rejestracja zmiany Statutu Spółki - Content (PL)
Polish 1.7 KB
2025-10-03 17:06
Regulatory News Service
Zawarcie przez spółkę zależną umowy z generalnym wykonawcą inwestycji - Content…
Polish 2.7 KB
2025-10-02 17:55
Legal Proceedings Report
Podsumowanie spotkania z Food and Drug Administration, (FDA) typu B dla CPL'36…
English 3.4 KB
2025-10-02 17:55
Legal Proceedings Report
Podsumowanie spotkania z Food and Drug Administration, (FDA) typu B dla CPL'36…
Polish 3.2 KB
2025-09-17 17:55
Audit Report / Information
Raport z przeglądu
Polish 218.2 KB
2025-09-17 17:55
Audit Report / Information
Raport z przeglądu
Polish 437.5 KB
2025-09-17 17:55
Management Discussion and Analysis
Sprawozdanie z działalności Zarządu
Polish 953.2 KB
2025-09-17 17:55
Interim Report
Sprawozdanie finansowe H12025
Polish 1.6 MB
2025-09-11 11:12
Report Publication Announcement
Aktualizacja informacji dotyczącej przekazywania raportów okresowych w 2025 rok…
Polish 1.9 KB
2025-08-04 15:16
Capital/Financing Update
Uzgodnienie z Europejskim Bankiem Odbudowy i Rozwoju głównych warunków udzielen…
Polish 1.5 KB
2025-07-16 21:15
Major Shareholding Notification
zal01_TCM_Celon_Notification_Form.pdf
English 89.7 KB
2025-07-16 21:15
Major Shareholding Notification
Otrzymanie zawiadomienia o przekroczeniu progu 5% udziału w ogólnej liczbie gło…
Polish 1.1 KB
2025-06-26 21:39
Post-Annual General Meeting Information
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zg…
Polish 888 bytes
2025-06-26 21:36
Post-Annual General Meeting Information
Uchwały podjęte przez ZWZ
Polish 221.8 KB

Automate Your Workflow. Get a real-time feed of all Celon Pharma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celon Pharma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.